Alliance for Pandemic Preparedness

Result for
Tag: antigen

March 17, 2021

Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands

Evaluation of the Roche SD Biosensor rapid antigen test for SARS-CoV-2 among asymptomatic outpatients demonstrated that test sensitivity was 84.9% and specificity was 99.5%. Around 98% of samples with a cycle threshold (Ct) below 30 (indicating higher viral load) were detected. Test sensitivity was higher (95.8%) among people who sought care within 7 days of…

March 9, 2021

Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission

A transmission model calibrated to the US population suggests that implementing weekly home-based SARS-CoV-2 antigen testing could avert 2.8 million infections and 15,700 deaths over 60 days. In contrast, a scenario with no testing anticipates 11.6 million infections and 119,000 deaths over the same time period. While the scenario with testing could cost an additional…

February 24, 2021

Self-Testing for the Detection of SARS-CoV-2 Infection with Rapid Antigen Tests

[Pre-print, not peer-reviewed] Self-testing for SARS-CoV-2 using rapid antigen detection kits (RDT) was found to have a high specificity (99.4%) and relatively high sensitivity (78%) to identify individuals infected with SARS-CoV-2 RNA below a low cycle-time (CT) value threshold.  Low CT values are associated with high viral load and the authors suggest that is a…

February 19, 2021

Multicenter Evaluation of the PanbioTM COVID-19 Rapid Antigen-Detection Test for the Diagnosis of SARS-CoV-2 Infection

A prospective multi-center study conducted in Spain found that the PanbioTM COVID-19 Ag Rapid Test Device, which tests for SARS-CoV-2 using nasopharyngeal swabs, has an overall sensitivity of 91% and specificity of 99%. Among the 128 asymptomatic participants who had close contact with a COVID-19 patient, there was full concordance in the 31 (24%) who…

January 19, 2021

Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020

The sensitivity of the BinaxNOW antigen test, compared to RT-PCR, was lower when testing specimens from asymptomatic (35.8%) than from symptomatic (64.2%) persons, based on 3,419 paired specimens from community testing in Arizona. Specificity was near 100% for both groups. Sensitivity was higher among the 96 specimens positive for viral culture (92.6% and 78.6% for…

January 13, 2021

Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-Throughput Drive-through Community Testing Site in Massachusetts

[Pre-print, not peer-reviewed] An evaluation of the Abbott BinaxNOW COVID-19 Ag Card in a drive-through community testing site in Massachusetts using anterior nasal swab RT-PCR for clinical testing found that BinaxNOW had very high specificity in both adults and children (100% for both) and very high sensitivity in newly symptomatic adults (96.5% within 7 days…

December 30, 2020

Field Performance and Public Health Response Using the BinaxNOW Rapid SARS-CoV-2 Antigen Detection Assay during Community-Based Testing

Among 3,302 persons tested for SARS-CoV-2 by BinaxNOW Rapid SARS-CoV-2 antigen detection assay in a community setting with 7.2% prevalence, rapid assay sensitivity was 100%, 98.5%, and 89% using RT-PCR Ct thresholds of 30, 35 and none, respectively. The assay maintained high sensitivity performance across ages and those with and without symptoms. Assay specificity was…

November 25, 2020

The Sensitivity of SARS-CoV-2 Antigen Tests in the View of Large-Scale Testing

A comparison of two point-of-care antigen tests to PCR testing concluded that the low sensitivity of antigen testing contributes to a significant risk of false negatives when used in symptomatic or asymptomatic COVID-19 patients. The two antigen tests exhibited sensitivities of 0.66 and 0.62 among all COVID-19 patients, 0.74 and 0.69 among symptomatic patients, and…